Tivozanib hydrochloride hydrate is the hydrate hydrochloride form of Tivozanib. It is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2, and 3, with IC50s of 30, 6.5, and 15 nM, respectively. It exhibits antitumor efficacy.
- Selective, orally active inhibitor for VEGFR-1, 2, and 3.
- Exhibits antitumor efficacy.
- Inhibits the phosphorylation of VEGFR-1, VEGFR-2, and VEGFR-3.
- Inhibits VEGF-induced proliferation and migration of HUVECs.
- Selectively inhibits VEGF-stimulated phosphorylation of MAPKs in endothelial cells.
- Exhibits antitumor efficacy against various cancers in athymic mice models.
- Reversibly suppresses vascular permeability and angiogenesis.